(P102) Adverse Effects in Older Patients with T2D Treated with SGLT2 Inhibitors

Sodium glucose co-transporter 2 inhibitors (SGLT2 inhibitors) are recommended as initial treatment in patients with T2D with cardiovascular and renal disease. These oral antidiabetic agents inhibit the proximal renal tubular reabsorption of glucose, coupled with sodium, leading to osmotic diuresis and natriuresis. Several reasons exist for discontinuing SGLT2 inhibitors in the ambulatory care setting including adverse effects (AEs). The reasons for discontinuation in an older patient population have not been well reported in the literature for older patients. This poster discusses a retrospective analysis with data extracted from Northeast Georgia Health System electronic health records for adult patients with T2D who discontinued an SGLT2 inhibitor between January 1, 2018, to January 31, 2023. The primary outcome was the presence of AEs in older patients.